Spironolactone and canrenoate-K: relative potency at steady state. (Record no. 865779)

MARC details
000 -LEADER
fixed length control field 01395 a2200421 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250511153724.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 197706s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0009-9236
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1002/cpt1977215602
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Ramsay, L
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 19770630
245 00 - TITLE STATEMENT
Title Spironolactone and canrenoate-K: relative potency at steady state.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Clinical pharmacology and therapeutics
Date of publication, distribution, etc. May 1977
300 ## - PHYSICAL DESCRIPTION
Extent 602-9 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Comparative Study; Journal Article
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Administration, Oral
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Canrenoic Acid
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Canrenone
General subdivision blood
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Dose-Response Relationship, Drug
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fludrocortisone
General subdivision antagonists & inhibitors
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Potassium
General subdivision urine
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pregnadienes
General subdivision pharmacology
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Sodium
General subdivision urine
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Solutions
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Spironolactone
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Tablets
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Therapeutic Equivalency
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Time Factors
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Asbury, M
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Shelton, J
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Harrison, I
773 0# - HOST ITEM ENTRY
Title Clinical pharmacology and therapeutics
Related parts vol. 21
-- no. 5
-- p. 602-9
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1002/cpt1977215602">https://doi.org/10.1002/cpt1977215602</a>
Public note Available from publisher's website

No items available.